

Form PTO-1449 (modified)		Atty. Docket No.: SOBL.P0051US	Serial No.: 10/598,356
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant: Kerstin MENANDER Robert E. SOBOL	
		Filing Date: August 11, 2008	Group: 1632
U.S. Patent Documents <i>None</i>	Foreign Patent Documents <i>None</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	"INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy—Introgen, RPR/INGN 201," NCBI Pubmed abstract, PMID: 12749760 of <i>Biodrugs</i> , 17:216-222, 2003.
	C12	Moon <i>et al.</i> , "Current status of gene therapy for lung cancer and head and neck cancer," <i>Clinical Cancer Research</i> , 9: 5055-5067, 2003.
	C13	Office Communication issued in Canadian Patent Application No. 2,557,326, dated May 31, 2011. (SOBL.P0051CA)

90529624.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.